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Abstract
Background: Current practice is to perform a completion axillary lymph node dissection (ALND)
for breast cancer patients with tumor-involved sentinel lymph nodes (SLNs), although fewer than
half will have non-sentinel node (NSLN) metastasis. Our goal was to develop new models to
quantify the risk of NSLN metastasis in SLN-positive patients and to compare predictive capabilities
to another widely used model.
Methods: We constructed three models to predict NSLN status: recursive partitioning with
receiver operating characteristic curves (RP-ROC), boosted Classification and Regression Trees
(CART), and multivariate logistic regression (MLR) informed by CART. Data were compiled from
a multicenter Northern California and Oregon database of 784 patients who prospectively
underwent SLN biopsy and completion ALND. We compared the predictive abilities of our best
model and the Memorial Sloan-Kettering Breast Cancer Nomogram (Nomogram) in our dataset
and an independent dataset from Northwestern University.
Results: 285 patients had positive SLNs, of which 213 had known angiolymphatic invasion status
and 171 had complete pathologic data including hormone receptor status. 264 (93%) patients had
limited SLN disease (micrometastasis, 70%, or isolated tumor cells, 23%). 101 (35%) of all SLN-
positive patients had tumor-involved NSLNs. Three variables (tumor size, angiolymphatic invasion,
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and SLN metastasis size) predicted risk in all our models. RP-ROC and boosted CART stratified
patients into four risk levels. MLR informed by CART was most accurate. Using two composite
predictors calculated from three variables, MLR informed by CART was more accurate than the
Nomogram computed using eight predictors. In our dataset, area under ROC curve (AUC) was
0.83/0.85 for MLR (n = 213/n = 171) and 0.77 for Nomogram (n = 171). When applied to an
independent dataset (n = 77), AUC was 0.74 for our model and 0.62 for Nomogram. The
composite predictors in our model were the product of angiolymphatic invasion and size of SLN
metastasis, and the product of tumor size and square of SLN metastasis size.
Conclusion: We present a new model developed from a community-based SLN database that
uses only three rather than eight variables to achieve higher accuracy than the Nomogram for
predicting NSLN status in two different datasets. 
Background
Current practice guidelines recommend a completion
axillary lymph node dissection for breast cancer patients
whose SLN contains metastatic tumor [1-3]. The risk of
morbidity that accompanies completion ALND seems jus-
tified for patients with NSLN metastases, because they
would undergo excision of residual cancer [4]. However,
50 to 65% of patients with tumor-involved SLNs do not
have additional nodal metastasis [5,6]. For them, ALND
offers no clear therapeutic benefit, provides no further
information for staging, and increases the cost of medical
care. Further, completion ALND is associated with sub-
stantial morbidity affecting up to 39% of patients, with a
nearly three-fold increased risk of lymphedema or
regional sensory loss [7-9]. Identifying SLN-positive
patients without NSLN metastases who could forgo com-
pletion ALND would improve the quality of life and
reduce costs for the majority of women with new diag-
noses of breast cancer.
Previous investigations have not identified predictors of
NSLN status with accuracy sufficient to change clinical
practice. This failure may be due to limited sample sizes or
single institution studies [5,6,10]. The majority of prior
investigations include sample sizes of less than two hun-
dred subjects, with the challenges of dealing with small
sample sizes leading to decreased predictive accuracy
when applied to the general population [5,6,10-12].
However in 2003 Van Zee et al. proposed a nomogram to
predict risk of NSLN metastasis based on an accrued pop-
ulation of 1075 cases of primary invasive breast cancer
[13]. The Memorial Sloan-Kettering Cancer Center
(MSKCC) Breast Cancer Nomogram (Nomogram) has
since been successfully applied internationally and
become the most commonly used predictive model for
NSLN involvement [14]. Use of a predictive nomogram
has been shown to be superior to expert opinion, to
improve clinical decision making, and to be partially
responsible for the decreasing frequency of ALNDs per-
formed [15,16]. However, use of the Nomogram is lim-
ited by its complexity, and inability to be applied if not all
patient characteristics are known [17]. Although the
Nomogram was based on a large sample size, its reported
predictive accuracy and its generalizability to patient pop-
ulations with dissimilar tumor characteristics or to non-
academic, non-quaternary care hospitals has been ques-
tioned [17-19].
Our goal was to identify characteristics of patients and
their tumors that predict NSLN status within the Bay Area
SLN Database, comprised of diverse patient populations
from one academic and 15 community-based medical
centers in Northern California and Oregon. We con-
structed three new models and contrasted their perform-
ance with the Nomogram. We provide a model that has
simpler input than the Nomogram and shows higher
accuracy for our diverse patient population and for
another population of SLN-positive patients with differ-
ent patient characteristics from Northwestern University.
We have created an internet-based calculator, the Stanford
Online Calculator, for validation testing and clinical
application.
Methods
Study patients
The Bay Area SLN Study for Detection of Axillary Metastasis
in Breast Cancer is a multi-institutional collaboration
involving 16 institutions in the Greater Bay Area of North-
ern California and Oregon, of which 15 are community
hospitals. A total of 1,040 patients underwent SLN biopsy
for biopsy-proven breast cancer between 1996 and 2002.
After excluding 256 patients (criteria shown in Additional
file 1), we analyzed 784 prospectively accrued subjects
with primary invasive breast carcinoma and clinically neg-
ative axilla who underwent SLN biopsy with completion
axillary lymph node dissection. 285 (36.4%) had tumor-
involved SLNs. Among the 285 SLN-positive patients, 213
had pathologic information regarding presence or
absence of angiolymphatic invasion (lymphovascular
invasion, LVI); 171 patients had complete pathologic
information on both angiolymphatic invasion and hor-
mone receptor status. The Northwestern test dataset wasBMC Cancer 2008, 8:66 http://www.biomedcentral.com/1471-2407/8/66
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compiled by chart review of all patients who underwent a
SLN biopsy at Northwestern Memorial Hospital in Chi-
cago, IL, between 2002 and 2006. It is comprised of 77
consecutively identified sentinel node positive patients
with invasive breast cancer who underwent completion
ALND and had complete pathologic information on
tumor type, tumor size, tumor grade, hormone receptor
status, HER2/neu status, angiolymphatic invasion status,
number of nodes removed, and size of sentinel node
metastases. Inclusion and exclusion criteria are similar to
that outlined for the Stanford patients in Additional file 1.
The Northwestern database was compiled by physicians
not involved in generation of the predictive models. The
Bay Area SLN study was performed under a protocol
approved by the Stanford University Administrative Panel
on Human Subjects in Medical Research and the Institu-
tional Review Boards of each participating institution. An
independent protocol was approved by the Institutional
Review Board of Northwestern University for retrospective
chart review and data collection to test the Stanford
Online Calculator and MSKCC Nomogram.
SLN biopsy and pathological evaluation
SLN biopsy has been described previously [20]. The SLN
was identified using peritumoral injection of 1% isosulfan
blue dye, filtered 99mTc sulfur colloid radioactive tracer, or
both, as decided by the operating surgeon. All lymph
nodes that were blue and/or focally radioactive and/or
suspicious by intraoperative palpation were denoted
SLNs. All SLNs were evaluated by step-sectioning with
hematoxylin and eosin (H&E) staining; in the Bay Area
SLN study, SLNs without metastasis detectable by H&E
underwent staining by immunohistochemistry (IHC)
[21]. IHC was performed on at least four levels of the SLN
using anti-keratin antibodies AE1 and CAM5.2. One
pathologist directed and interpreted IHC studies on every
SLN excised at 14 of the 16 participating institutions in
the Bay Area SLN Study. NSLNs were evaluated by H&E
only, without serial sectioning. In the Northwestern
series, negative SLNs did not undergo IHC testing and
individual tumor cells or clusters were identified on H&E
only.
Statistical analyses
Thirteen characteristics were studied individually for pre-
dicting NSLN status: patient age, tumor histology, tumor
size (as a continuous variable and as T size by 6th edition
AJCC criteria), tumor grade [22], estrogen receptor (ER)
status, progesterone receptor (PR) status, HER2/neu sta-
tus, presence of angiolymphatic invasion, number of
SLNs excised, number of positive SLNs, size of nodal
metastasis (recorded according to revised 6th edition AJCC
criteria) [23], and method of detecting nodal metastasis
(H&E or IHC). Univariate testing was done with χ2 statis-
tics and Wilcoxon rank sums. For multivariate analyses,
tree-based classification and logistic regression were per-
formed [24,25]. Recognizing that some characteristics can
be interdependent, we performed multivariate analyses
with two approaches whereby interactions among varia-
bles are emphasized: recursive partitioning via receiver
operating characteristic (RP-ROC) [26] curves and
(boosted) classification and regression trees (CART®)
[24,27,28].
RP-ROC uses the relationship of sensitivity and specificity
to calculate the "best value" of each variable for predicting
NSLN status. It then chooses the variable with best value.
Successive partitioning permits use of ROC curves to com-
pare predictive accuracy and best cut point on "best
selected variable." Partitioning of the population into
subgroups continues until only patients with or without
NSLN metastases are segregated to the group, or until the
putative p value of the split exceeds 0.01. RP-ROC was per-
formed as is described in detail by Kraemer [26] (software
available from Sierra-Pacific MIRECC [29]).
CART as we applied it uses both cross-validation and vot-
ing methods (boosting) to assess the stability and
improve the accuracy of the final model [24,27], (software
available from Salford Systems, v5 [30]). Splits are chosen
by what is termed the Gini criterion, whose goal is to
render nodes of the tree as "pure" as possible in terms of
positive or negative NSLN status. Boosting is a method
designed to focus on "hard to classify" observations. In all
classifications, there is dependence on the products by
class of priors and costs of misclassification. For all classi-
fication trees, mixed priors (an average of equal priors and
prevalence-based priors) were used. After surveying eight-
een breast surgeons expert in SLN biopsy and not associ-
ated with this study, the costs of a false-positive and false-
negative NSLN were set at 3 and 10, respectively.
A third technique, multivariate logistic regression (MLR)
informed by CART, was performed with variable selection
based on paths from the root to the five terminal nodes of
unboosted CART [31]. Odds ratios were calculated indi-
vidually for all terms that were candidates for inclusion in
subsequent analyses. Those terms retained were entered
into the MLR by forward selection based on the likelihood
ratio. Wald statistics and odds ratios were determined for
variables significant at putative p < 0.01 within the regres-
sion model [32]. A cutoff p < 0.01 was chosen in the inter-
est of our ending with a focused, concise, predictive
model.
In constructing the predictive models of NSLN status, we
used tumor characteristics that were significant by univar-
iate testing (Table 1): tumor size, tumor grade, ER status,
PR status, angiolymphatic invasion, size of SLN metasta-
sis, and SLN metastasis identification method. StatisticalBMC Cancer 2008, 8:66 http://www.biomedcentral.com/1471-2407/8/66
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Table 1: Characteristics of NSLN- and NSLN+ cases among SLN+ patients (Bay Area SLN Database).
Tumor-free NSLN Tumor-involved NSLN Univariate 
P ∫
Multivariate 
P ∫∫
%NSLN+ 
(NSLN+/SLN+)
TOTAL SLN+
Patient and Tumor 
Characteristics
Number of 
Pts (n = 184)
% Mean SEM* Number of 
Pts (n = 101)
% Mean SEM* Number of 
Pts (n = 285)
%
Patient Age (years) 55.8 0.89 53 1.14 0.084 NA
Tumor Type
Infiltrating Ductal 
Carcinoma
159 86 87 86 0.781 NA 35% 246 86.3
Invasive Lobular 
Carcinoma
18 10 9 9 33% 27 9.5
Mixed Carcinoma 6 3 5 5 45% 11 3.9
Tubular Carcinoma 1 1 0 0 0% 1 0.4
Tumor size (cm) 2.11 0.1 2.97 0.18 <0.001 <0.001
Tumor size (AJCC) 0.001 0.045
T1 117 64 39 39 25% 156 54.7
T1a (mic) 1 1 0 0 0% 1 0.4
T1a 6 3 2 2 25% 8 2.8
T1b 19 10 3 3 14% 22 7.7
T1c 91 49 34 34 27% 125 43.9
T2 59 32 50 50 46% 109 38.2
T3 8 4 12 12 60% 20 7.0
Tumor grade† 0.001 0.736
G1: Nottingham 
combined histologic 
score 3–5
68 37 23 23 25% 91 31.9
G2: Nottingham 
combined histologic 
score 6–7
81 44 39 39 33% 120 42.1
G3: Nottingham 
combined histologic 
score 8–9
35 19 39 39 53% 74 26.0
ER status 0.004 0.079
Negative 17 9 21 21 55% 38 13.3
Positive 134 73 60 59 31% 194 68.1
Unknown 33 18 20 20 38% 53 18.6
PR status 0.015 0.869
Negative 35 19 31 31 47% 66 23.2
Positive 116 63 50 50 30% 166 58.2
Unknown 33 18 20 20 38% 53 18.6
HER2/neu expression 0.256 NA
Not overexpressed, 0+ 
or 1+
81 44 38 38 32% 119 41.8
Equivocal, weak 
overexpression, 2+
2 1 2 2 50% 4 1.4
Overexpressed, 3+ 29 16 23 23 44% 52 18.2
Unknown 72 39 38 38 35% 110 38.6
Angiolymphatic 
invasion
<0.001 <0.001
None 95 52 23 23 19% 118 41.4
Present 25 14 70 69 74% 95 33.3
Unknown 64 35 8 8 11% 72 25.3
Sentinel Lymph Node 
Characteristics
No. SLNs Removed 1.96 0.07 1.87 0.09 0.511 NA
= 1 71 39 42 42 0.806 37% 113 39.6
= 2 67 36 37 37 36% 104 36.5
>2 46 25 22 22 32% 68 23.9
No. SLNs Tumor-
involved
1.33 0.05 1.39 0.07 0.426 NA
= 1 137 73 71 70 0.679 34% 208 73.0
= 2 38 21 23 23 38% 61 21.4
>2 9 6 7 7 44% 16 5.6
Size of SLN 
metastases§
<0.001 <0.001
Isolated tumor cells or 
clusters ≤ 0.2 mm
61 33 3 3 4.7% 64 22.5
Micrometastases, >0.2 
mm to 2 mm
117 64 83 82 42% 200 70.2
Macrometastases, >2 
mm
6 3 15 15 71% 21 7.4BMC Cancer 2008, 8:66 http://www.biomedcentral.com/1471-2407/8/66
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modeling of NSLN status allowed calculation of both the
predictive capacity of significant variables and the critical
interactions between and among variables, such as
increasing angiolymphatic invasion with increasing
tumor size. All models used identical variables, although
not identical patients. RP-ROC requires complete data,
where no values of features are missing, whereas CART
does not. Instead, CART relies on the subtle notion of
"surrogate split" [24]. Thus, boosted CART analyses were
performed on all 285 SLN-positive patients as well as sub-
sets with more complete information, while RP-ROC and
MLR analyses were performed on the 213 patients with
complete data for angiolymphatic invasion and on the
171 patients with complete data for angiolymphatic inva-
sion and hormone receptor status.
The MSKCC Breast Cancer Nomogram for Prediction of
ALN Status [13] (Nomogram) was applied to our patient
population and, to provide fair comparison, calculated for
only the 171 patients with complete information on the
eight variables required for its application (pathologic size
of primary tumor, tumor type with nuclear grade if ductal,
LVI, multifocality of primary tumor, ER status, method of
detecting SLN metastasis, number of positive SLNs, and
number of negative SLNs; a ninth variable, whether a fro-
zen section was performed, was not applicable to our
patients). ROC curves were constructed for the Nomo-
gram and the other methods to compare the area under
the curve (AUC). Internal validation was performed by
10-fold cross-validation, as previously described [27].
Data were divided at random into 10 parts, as equal as
possible in size. CART (in this instance, but more gener-
ally any other procedure) was then computed successively
for 9/10 of the data with the remaining piece held out as
"test sample." This was repeated 10 times and results on
the 10 test samples were averaged. Cross-validation is an
internal validation method that estimates performance on
subsequent subjects by eliminating bias that owes to
using the same, or even a portion of the same, data for
both modeling and testing. However, even with internal
validation, bias and variability can be introduced into
subsequent analyses if the prevalence of features that pre-
dict outcome is different in future datasets than in the
dataset from which the model was developed. The differ-
ences in distribution of variables (and in synergistic inter-
actions between variables) for an original and a
subsequent test dataset impacts a model's performance on
future datasets and applies both to our models and to that
of the Nomogram. For this reason, we tested our model
and the Nomogram on the Northwestern dataset that dif-
fered from our original dataset in its distribution of
patient, tumor, and sentinel node variables.
ROC curves were constructed for the Nomogram and the
MLR informed by CART model for the Bay Area SLN study
dataset and the independent Northwestern dataset.
Statistical analyses were performed with R [33].
Results
Table 1 and Additional files 2 and 3 describe in detail the
SLN-negative and SLN-positive patients of the Bay Area
SLN dataset. As expected, the incidence of SLN metastasis
increased with increasing tumor size: 29% of T1, 51% of
T2, and 80% of T3 tumors had SLN metastasis. As tumor
size increased over 1 cm, the incidence of angiolymphatic
invasion doubled for both SLN-positive and SLN-negative
patients but was higher for SLN-positive patients (Addi-
tional file 3). Among all 784 patients, the total number of
women with any axillary lymph node metastasis was 316
(40%), including 31 (9.8%) with a false negative SLN
(Additional file 2).
Among SLN-positive cases, the average number of SLNs
removed was 1.91, with metastatic disease limited to a
single SLN in 73%. Among tumor-involved SLNs, 23%
contained isolated tumor cells or clusters (ITCs, ≤ 0.2
mm); 70% contained micrometastases (>0.2 mm to 2
mm); and 7% contained macrometastases (>2 mm). All
SLNs containing ITCs required IHC for detection. Only
one of 200 cases with SLNs involved by micrometastasis
was not observed on H&E and required IHC staining for
identification. All 21 cases with SLN macrometastasis
were identified by H&E staining (Additional file 2).
Of 285 patients with tumor-involved SLNs, 101 (35.4%)
were found to have NSLN metastases, with tumor metas-
tases to two or more NSLNs in the majority of cases
Sentinel lymph node 
metastases 
identification
<0.001 NA
Hematoxylin and eosin 
staining
122 61 98 97 45% 220 77.2
Immunohistochemistry 62 34 3 3 4.6% 65 22.8
∫ Univariate analyses calculated by χ 2 test and Wilcoxon rank sum test.
∫∫ Multivariate analyses calculated by logistic regression of significant factors by univariate analysis.
*SEM, standard error of the mean.
†Determined according to modified Scarff-Bloom-Richardson grading system.
§Determined according to AJCC criteria, 6th ed.
NA, variable not included in multivariate analysis (not an independent factor or not significant in univariate analysis)
Table 1: Characteristics of NSLN- and NSLN+ cases among SLN+ patients (Bay Area SLN Database). (Continued)BMC Cancer 2008, 8:66 http://www.biomedcentral.com/1471-2407/8/66
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(median number of positive NSLNs 2; mean 3.5; range
1–19) (Additional file 2). By univariate analyses, 8 varia-
bles were highly predictive of NSLN status: tumor size (in
cm), tumor size by AJCC T classification, tumor grade, ER
status, PR status, angiolymphatic invasion, size of SLN
metastasis, and whether the nodal metastasis was identi-
fied by H&E or IHC (Table 1). Of patients whose SLN was
identified by H&E, 45% had NSLN metastases, whereas
only 4.6% of patients whose SLN was identified by IHC
had NSLN metastases (p < 0.001). Size of SLN metastasis
and staining method for metastasis identification are
highly correlated (p = 0.02, by χ2 testing) and therefore are
not independent predictors of NSLN status. Thus, staining
method for identifying tumor-involvement was not
included in the multivariate analysis shown in Table 1. By
multivariate analysis, tumor size, angiolymphatic inva-
sion, and size of SLN metastasis remained significantly
predictive of NSLN status (p < 0.001 by unconditional
testing). Of the 285 patients with SLN metastases, NSLN
metastases were found in 25% of patients with T1 tumors;
in 46% with T2 tumors; and in 60% with T3 tumors (Fig-
ure 1A). When angiolymphatic invasion was present,
there was a 3.9-fold increase in NSLN metastases (74% vs.
19%, Figure 1B). Among patients with isolated tumor
cells or clusters within the SLN, 4.7% had NSLN metasta-
sis; whereas 42% of patients with micrometastasis and
71% with macrometastasis had NSLN involvement (Fig-
ure 1C and Table 1).
The models generated by RP-ROC (Figure 2A) and CART
(Figure 2B, Additional files 4 and 5) ultimately included
tumor size, angiolymphatic invasion, and size of SLN
metastasis. At the final split, likelihood of NSLN metas-
tases partitioned into groups by level of risk. The signifi-
cant predictors as selected by multivariate tree-based
modeling were tested individually, as well as all iterations
of predictors, in a MLR model. Variables entered were
tumor size, angiolymphatic invasion, and size of SLN
metastasis (Table 2). Size of SLN metastases interacts with
the status of angiolymphatic invasion; that is, the impact
of the size of SLN metastases upon the presence or
absence of NSLN metastases depends on whether there
was angiolymphatic invasion. The tree suggests that one
might enter angiolymphatic invasion (scored as 1 if
present, 0 if absent) not only multiplied by SLN metasta-
sis size to the first power, but also as the product of angi-
olymphatic invasion and the square of SLN metastasis size
(scored as an ordinal variable with values of 1, 2, and 3
corresponding to the size classification of isolated tumor
cells, micrometastasis, or macrometastasis). The MLR
model identified two highly predictive composite varia-
bles: the product of angiolymphatic invasion and size of
SLN metastasis (p  < 0.0001, odds ratio of 4.73 with
approximate 95% confidence interval 3.11–7.20) as well
as the product of tumor size and squared size of SLN
metastasis (p < 0.0001, odds ratio of 1.18 with 95% con-
fidence interval 1.10–1.26). We emphasize that p-values
Fraction of patients in Bay Area SLN Database with and without NSLN metastases in relation to (A) tumor stage, (B) angiolym- phatic invasion, and (C) size of SLN metastasis Figure 1
Fraction of patients in Bay Area SLN Database with and without NSLN metastases in relation to (A) tumor 
stage, (B) angiolymphatic invasion, and (C) size of SLN metastasis.
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are only approximate because CART was used as preproc-
essor to manufacturing the predictive variables. However,
these p-values are so small, and the clinical logic so com-
pelling, that we do not doubt their practical, let alone sta-
tistical, significance.
Table 3 compares the sensitivities, specificities, and pre-
dictive accuracies of our three models, RP-ROC, boosted
CART, and MLR, all computed with 10-fold cross valida-
tion [26]. As different models require different informa-
tion, we evaluated models for the entire group (n = 285,
only possible for CART) and subsets that contained com-
plete information on angiolymphatic invasion (n = 213),
and alternatively, on angiolymphatic invasion and ER sta-
tus (n = 171). Cross-validated sensitivities/specificities of
the three technologies for the group with known angiol-
ymphatic invasion status (n = 213) were 79%/76% for RP-
ROC, 88%/71% for boosted CART, and 78%/86% for
MLR. Cross-validated specificity of boosted CART when
inferred for the entire dataset (n = 285) was lower than
when calculated using known values for angiolymphatic
invasion (n = 213), suggesting that angiolymphatic inva-
sion is informative in our dataset. This is supported by the
continued selection of angiolymphatic invasion in CART
modeling when patients have known angiolymphatic
invasion status (n = 213) and known angiolymphatic sta-
tus and ER status (n = 171) (Additional files 4 and 5,
respectively). Overall diagnostic accuracy, based on areas
Tree diagrams for RP-ROC and CART Figure 2
Tree diagrams for RP-ROC and CART. As CART is able to impute missing data, it was calculated for all SLN positive 
patients, n = 285. RP-ROC requires complete data and was calculated for patients with known angiolymphatic invasion status, 
n = 213 (Bay Area SLN Database).
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1 NSLN+ / 15 NSLN-
Yes (8)
3 NSLN+ / 5 NSLN-
Yes (8)
3 NSLN+ / 5 NSLN-
No (71)
66 NSLN+ / 5 NSLN-
No (71)
66 NSLN+ / 5 NSLN-
Yes (6)
2 NSLN+ / 4 NSLN-
Yes (6)
2 NSLN+ / 4 NSLN-
No (81)
8 NSLN+ / 73 NSLN-
No (81)
8 NSLN+ / 73 NSLN-
No (31)
13 NSLN+ / 18 NSLN-
No (31)
13 NSLN+ / 18 NSLN-
Yes (23)
1 NSLN+ / 22 NSLN- 1 NSLN+ / 22 NSLN-
No (119)
74 NSLN+ / 45 NSLN- 74 NSLN+ / 45 NSLN-
Yes (7)
3 NSLN+ / 4 NSLN-
Yes 
3 NSLN+ / 4 NSLN-
No (99)
9 NSLN+ / 90 NSLN - 9 NSLN+ / 90 NSLN -
No (37)
14 NSLN+ / 23 NSLN- 14 NSLN+ / 23 NSLN-
SLN+ patients (285)
101 NSLN+ / 184 NSLN-
Tumor size <2.75cm?
6% NSLN+
38% NSLN+ 93% NSLN+ 33% NSLN+ 10% NSLN+
42%NSLN+
4% NSLN+ 62% NSLN+
43% NSLN+ 9% NSLN+
38% NSLN+BMC Cancer 2008, 8:66 http://www.biomedcentral.com/1471-2407/8/66
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under the ROC curve [34] (AUC), for predicting NSLN
metastasis among patients in our database was greatest by
MLR (83% and 85%) for the subsets of patients for whom
the computation was possible (n = 213 and n = 171,
respectively). Further, we applied the Nomogram to our
SLN-positive patients who had complete data available
for entry of its eight variables (n = 171, all patients with
known angiolymphatic invasion status and ER status).
Figure 3 shows a graph of the ROC curve that devolves
from our MLR using our two composite variables (n =
213) and the ROC curve that devolves from the Nomo-
gram (n = 171). Because much preprocessing has gone
into our computations, p-values we might report (regard-
ing a null hypothesis that the "true" areas under the curves
are equal) would be suspect. However, the diagnostic
accuracy or area under the curve (AUC) for our MLR is
83% (95% confidence interval 0.81–0.86), and the AUC
for the Nomogram is 77% (95% confidence interval
0.73–0.81). When we use the same patients as used in the
Nomogram for the MLR calculation (n = 171), our model
achieves cross-validated AUC of 85% (95% confidence
interval 0.81–0.89). Given that only three variables were
used to calculate our MLR, the difference is noteworthy.
Finally, the MLR and Nomogram were applied to a data-
base of 77 patients who received ALND for positive SLNs
at Northwestern University (Additional file 6). The SLN
metastases in this dataset were identified by H&E stain
without IHC. Among the 77 SLN positive patients, 61%
had T1 tumors, 36% had T2 tumors, and 2.6% had T3
tumors. Angiolymphatic invasion was present in 68% of
patients' tumors, and the SLN metastases in the North-
western dataset were predominantly of large tumor bur-
den with 56% having macrometastasis. NSLN metastases
were present in 24 patients (31%). This is in contrast to
the Bay Area SLN dataset with 55% T1 tumors, 38% T2
tumors, and 7% T3 tumors; 45% with angiolymphatic
invasion (when angiolymphatic invasion status was
known); 7% with macrometastasis; and 35% NSLN
metastases (Table 1 and Figure 1). Although the North-
western tumors were somewhat smaller, the higher per-
centage of angiolymphatic invasion and SLN
macrometastases suggest more biologically aggressive dis-
ease in their dataset, yet they had a slightly lower percent-
age of NSLN metastasis.
Both the MLR model and the Nomogram performed less
well when applied to the Northwestern dataset; however,
the MLR model was supported with an AUC of 77% (95%
confidence interval 0.67–0.80). This is superior to the per-
formance of the Nomogram among this population, 62%
(95% confidence interval 0.55–0.68) (Figure 4).
Discussion
Sentinel lymph node biopsy is a major advance in the
treatment of women with breast cancer [35]. If no SLN
metastases are identified, the likelihood of additional
NSLN involvement is 9.8% in our series. Though above
the goal false-negative rate proposed by the American
Society of Breast Surgeons, this is comparable to that
reported in NSABP-32 and recently by both Lyman and
Veronesi ranging 9.7%, 8.4%, and 8.8% respectively
[1,36,37]. Of our patients with positive SLNs, the majority
presented with micrometastasis, 70%, or isolated tumor
cells, 22%. Thus, our population contains a predomi-
nance of limited SLN disease burden relative to prior
reports, including van Rijk's reported rate of 23% for
micrometastasis and 16% for isolated tumor cells [38].
This may be important as suggested by Alran et al. who
showed lower performance of the Nomogram in patients
with only micrometastases [19]. Despite the seemingly
low sentinel node tumor burden, 35% had NSLN metas-
tases upon completion ALND. Unfortunately, no combi-
nation of clinical and/or pathologic characteristics
enabled identification of all SLN-positive patients at risk
for NSLN metastases. Although SLN-positive patients will
Table 2: Multivariate Logistic Regression (MLR) analysis informed by CART for predicting NSLN metastasis among SLN+ patients (n = 
213) (Bay Area SLN Database).
Variable or Composite Variable Significance Wald Statistic OR (95% CI)
Angiolymphatic Invasion 0.024 a a
Tumor Size 0.508 a a
Size of SLN Metastasis 0.173 a a
Angiolymphatic Invasion × Tumor Size 0.166 a a
Angiolymphatic Invasion × Size of SLN Metastasis <0.0001 52.7 4.73 (3.11–7.20)
Angiolymphatic Invasion × (Size of SLN Metastasis)2 0.041 a a
Tumor Size × Size of SLN Metastasis 0.888 a a
Tumor Size × (Size of SLN Metastasis)2 <0.0001 22.6 1.18 (1.10–1.26)
Tumor Size × Size of SLN Metastasis × Angiolymphatic Invasion 0.471 a a
Tumor Size × (Size of SLN Metastasis)2 × Angiolymphatic Invasion 0.761 a a
OR: odds ratio; 95% CI: 95% confidence interval. a No Wald statistic or odds ratio calculated for variables not significant at P < 0.01 with respect to 
multivariate modelBMC Cancer 2008, 8:66 http://www.biomedcentral.com/1471-2407/8/66
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receive systemic chemotherapy and/or hormone therapy,
it is unknown whether occult NSLN metastases are eradi-
cated by adjuvant treatment. Until results of large pro-
spective clinical trials can demonstrate no long-term
increase in mortality from omitting ALND in the setting of
systemic therapy, prophylactic ALND for patients with
tumor-involved SLNs, including those with and without
NSLN involvement, remains standard surgical care [39-
43]. However, in practice, it is the patient and her physi-
cian who decide whether or not a completion axillary dis-
section is performed. This decision may be informed
using online calculators such as the Nomogram and the
one presented here.
Based on a multi-institutional sample set larger than most
prior studies, we found that univariate predictors of NSLN
status include tumor size (in cm and by AJCC T size clas-
sification), tumor grade, hormone receptor status (ER and
PR), angiolymphatic invasion, size of SLN metastasis, and
whether nodal tumor involvement is identified by H&E.
By multivariate analyses, tumor size, angiolymphatic
invasion, size of SLN metastases, and products of these
variables predict NSLN tumor involvement. Others have
also discovered the predictive strength of each of the three
simple characteristics [5,6,10,44-50], although here we
confirm their collective power in a unique way. Addition-
ally, we found that angiolymphatic invasion is as strong a
predictor of NSLN metastasis as is size of SLN metastasis.
For women with isolated tumor cells in the SLN, we found
a 4.7% chance of NSLN involvement, similar to Calhoun
and Giuliano's reported NSLN-involvement rate of 4.9%
for the same subset of patients, and comparable to or
lower than that found previously, 10–15% [47,51,52].
ROC curves for MLR informed by CART calculation in blue, AUC = 0.83, and Nomogram in green, AUC = 0.77, when applied  to the Bay Area SLN Database Figure 3
ROC curves for MLR informed by CART calculation in blue, AUC = 0.83, and Nomogram in green, AUC = 
0.77, when applied to the Bay Area SLN Database. Note that MLR informed by CART calculation was done for larger 
group of patients (n = 213). When it was performed for the same patient group as the Nomogram (n = 171), AUC increased 
to 0.85.
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The benefits of no further axillary dissection must be
weighed against the risk of harboring axillary metastasis
that may potentially seed occult metastatic disease. Clini-
cal context, with consideration of a patient's expected life-
span and associated health problems, may impact the def-
inition of a "minimal acceptable risk." Recommendations
for clinical practice are difficult because the risk of NSLN
metastasis in SLN-positive patients with isolated tumor
cells is comparable or lower than the risk of NSLN metas-
tases in patients without SLN metastases (9.8% in our
study) [53]. These issues are being studied in large-scale
prospective clinical trials [40,41]. Future molecular tech-
nologies may also provide guidance [54,55].
Our goal was to identify patients with tumor-free NSLNs
who, with near certainty, may be spared completion
ALND. Using multivariate tree-based modeling by RP-
ROC, boosted CART, and MLR informed by CART, we
identified tumor size, angiolymphatic invasion, and size
of SLN metastasis as characteristics that optimized stratifi-
cation of NSLN status. These refined, statistical analyses
demonstrated a highly synergistic interaction between
size of SLN metastasis and angiolymphatic invasion on
risk of NSLN metastasis. Our models (Figures 2, Addi-
tional files 4 and 5) stratified patients with tumor-
involved SLNs into four risk groups for having NSLN
metastasis: low risk (10% or less), moderate risk
(30–45%), high risk (about 60%), and very high risk
(greater than 90%).
MLR modeling of NSLN status that was informed by CART
in its selection of predictors provided the most accurate
cross-validated technique for predicting NSLN metastases
for patients with known angiolymphatic invasive status,
with accuracy superior to boosted CART, RP-ROC, and the
Memorial Sloan-Kettering Breast Cancer Nomogram.
When applied to the Bay Area SLN Database, the Nomo-
gram had an AUC of 77%. This compares with the accu-
racy of the Nomogram for the original MSKCC
population (76%) and for a prospective cohort at MSKCC
(77%) [13]. Seven subsequent studies have tested the
Nomogram and show an accuracy of 63% to 86%, though
as low as 54% when applied only to patients with SLN
micrometastases [14,17-19,56-60]. In contrast, our MLR
informed by CART model performed equally well among
patients with isolated tumor cells, micrometastases, or
macrometastases. Relative importance of size of SLN
metastasis in the Nomogram is determined by method of
detection including IHC, serial H&E, routine analysis, ver-
sus frozen section (among the subset for which this is per-
formed) [13]. The improved predictive accuracy of the
MLR model informed by CART, particularly among
patients with isolated tumor cells or micrometastasis, may
be due to the relative weight ascribed to the specific size of
Table 3: Model comparisons for predicting NSLN metastasis among SLN+ patients (Bay Area SLN Database).
For all SLN+ Pts (n = 285) For pts with known 
angiolymphatic invasion status 
(n = 213)
For pts with known 
angiolymphatic invasion and ER 
status (n = 171)
RP-ROC with 10-fold cross 
validation
Sensitivity (%) 78.8 83.2
Specificity (%) 75.5 78.1
Diagnostic Accuracy by AUC (%) 76.7 80.2
Boosted CART with 10-fold 
cross validation
Sensitivity (%) 78.2 87.9 89.0
Specificity (%) 62.0 71.4 74.7
Diagnostic Accuracy by AUC (%) 67.7 77.5 80.3
Multivariable logistic regression 
with 10-fold cross validation
Sensitivity (%) 78.0 78.9
Specificity (%) 86.2 88.3
Diagnostic Accuracy by AUC (%) 83.3 84.9
MSKCC Breast Cancer 
Nomograma
Diagnsotic Accuracy by AUC (%) 76.7
a Memorial Sloan-Kettering Cancer Center Breast Cancer Nomogram for Prediction of Axillary Lymph Node Metastasis applied to SLN+ pts in 
Stanford dataset who have complete data for all Nomogram variablesBMC Cancer 2008, 8:66 http://www.biomedcentral.com/1471-2407/8/66
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SLN metastasis in our model. Application of our MLR
model to other patient populations is required to validate
its performance.
Considering the risk of potential bias due to low sentinel
node tumor burden in our dataset, we applied both our
model and the MSKCC Nomogram to an independent
dataset of 77 SLN positive patients who underwent com-
pletion ALND. These cases were not identified by IHC and
this dataset contained cases with a much larger tumor bur-
den: 56% of cases contained macrometastasis in the SLN
compared to 7% of the Bay Area SLN dataset. Again, the
MLR model showed superior performance to the Nomo-
gram. However, the performance of both models
decreased compared to the Bay Area SLN Database: the
Stanford Online Calculator generated an AUC of 0.74, or
74%, and the Nomogram generated an AUC of 0.62, or
62%. This raises concern regarding the generalizable
nature of any model. An underlying reason why neither
model performed as well as anticipated is that when a
model is developed based on data from one group of
patients, and the model is subsequently applied to data
from a different group of patients, performance is gener-
ally diminished [24,27]. This is due to differences in the
distributions of predictive features and differences in the
synergistic impact (interactions) between and among
these features in different groups of patients. Thus a
model developed in one group of patients would not be
expected to perform as well for a different group of
patients, even if the performance of the model was vali-
dated internally (cross-validated) on the original group.
Table 1 and Additional file 6 shows differences in the dis-
tribution of the three variables in our model – tumor size,
size of SLN metastasis, and angiolymphatic invasion –
ROC curves for MLR informed by CART calculation in blue, AUC = 0.74, and Nomogram in green, AUC = 0.62, when applied  to the Northwestern test set (n = 77) Figure 4
ROC curves for MLR informed by CART calculation in blue, AUC = 0.74, and Nomogram in green, AUC = 
0.62, when applied to the Northwestern test set (n = 77). 24 patients had NSLN metastasis in this dataset.
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between patients in the Bay Area SLN Database and
Northwestern series. As we would also expect the interac-
tions of these variables to be different for both groups, we
believe these factors in aggregate may be responsible for
our findings.
The predictive accuracy of the Nomogram requires assess-
ment of eight tumor characteristics [13,14,17,18,56]. A
hazard of multi-variable modeling is that its overall accu-
racy is dependent upon the accuracy and precision with
which each individual variable is determined. Our MLR
confirmed the importance of two composite variables
from only three tumor characteristics: 1) the size of SLN
metastasis when angiolymphatic invasion is present, and
2) tumor size times the square of the size of SLN metasta-
sis. The first composite variable reflects the synergism
between angiolymphatic invasion and size of SLN metas-
tasis; the second involves tumor burden. Using these two
composite variables, AUC is 83% or 85% compared to the
Nomogram's AUC of 77% that relies on eight variables.
By using statistical methods which allow assessment of
the variable-variable interactions we demonstrate supe-
rior accuracy with fewer required variables. Our model is
the first proposed which emphasizes the synergistic inter-
actions among patient characteristics. By reducing the
required variables, we are hopeful the MLR model may be
applied a larger population of patients, without excluding
those with incomplete, unavailable, or pending patho-
logic data.
Missing pathologic data is problematic for breast cancer
patients nationwide. Though the generalizability of our
model may have benefited from the diverse population
represented, obtaining complete clinicopathologic infor-
mation was partially limited by enrollment across 16
institutions during the years of our study, 1996–2002.
Approximately 25% of our 285 SLN-positive patients had
no histologic analysis for angiolymphatic invasion. Of the
213 patients with angiolymphatic data present, another
19.7% had no ER status performed or recorded. This is
comparable to the 17.1% of invasive breast cancer
patients without recorded ER status in 13 registries of the
national Surveillance, Epidemiology, and End Results
(SEER) database from 1999–2003 [61] (unpublished
data, Jeffrey lab); presence of angiolymphatic invasion
status was not requested by SEER. Thus, we analyzed our
data using three patient groups: the entire SLN-positive
dataset of 285 patients; 213 SLN-positive patients who
had complete information on angiolymphatic invasion;
and 171 SLN-positive patients who had complete infor-
mation on angiolymphatic invasion and ER status. Even
applying the smallest dataset, more SLN-positive patients
are analyzed than in most other published studies.
Though not directly compared among identical patient
populations, the AUC of our model is also superior to that
of M.D. Anderson Cancer Center scoring system (70%)
and the Hôpital Tenon scoring system derived in Paris,
France (68%), as recently reported by Dauphine et al.
[59,62,63]. Calculations using our MLR model are easily
done over the internet with the Stanford Online Calcula-
tor [64]. We encourage others to access and test our model
and directly compare it with other models for evaluating
risk of NSLN metastasis.
Although no modeling technique has been able to iden-
tify patients without any risk of NSLN metastasis, Park et
al. recently argued that ALND may be reasonably elimi-
nated among patients with approximately 9% or less pre-
dicted risk of NSLN involvement [16]. A low risk subset of
287 patients with SLN metastasis were followed in a non-
randomized study with a 2% observed rate of local recur-
rence. This recommendation, however, is limited by a fol-
low-up of only 23 months. We expect that data from two
large prospective clinical studies, NSABP-32 and Ameri-
can College of Surgeons trial Z0011, will more definitively
resolve questions regarding the optimal surgical manage-
ment of SLN-positive patients [40,41]. In the meantime,
we hope that our calculator may provide further guidance
for risk evaluation.
Conclusion
Fewer than half of women undergoing completion axil-
lary lymph node dissection (ALND) for breast cancer will
have non-sentinel node (NSLN) metastasis. We present a
new model and the Stanford Online Calculator developed
from a Northern California and Oregon database with
superior accuracy and simplicity (three versus eight
required patient variables) compared to the Memorial
Sloan-Kettering Breast Cancer Nomogram for our dataset
and another independent dataset. We hope that other
institutions will test our model using their datasets, which
will contain different patient demographics, to validate its
accuracy and to refine in which populations it may be best
used. Further investigation of predictive models to stratify
risk of non-sentinel lymph node metastasis will better
define their role in guiding clinical decision-making,
while we await the results of larger randomized trials.
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